{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:24:05Z","timestamp":1793838245800,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["53248693"],"award-info":[{"award-number":["53248693"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["09150172010067"],"award-info":[{"award-number":["09150172010067"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["AdG2019-884796"],"award-info":[{"award-number":["AdG2019-884796"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["LSHM18055-5GF"],"award-info":[{"award-number":["LSHM18055-5GF"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["LSHM22042-SGF"],"award-info":[{"award-number":["LSHM22042-SGF"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022115","name":"Dutch Arthritis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022115","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","award":["18-1-205"],"award-info":[{"award-number":["18-1-205"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","award":["17-1-402"],"award-info":[{"award-number":["17-1-402"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","award":["15-2-402"],"award-info":[{"award-number":["15-2-402"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["777357"],"award-info":[{"award-number":["777357"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaut.2024.103320","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T14:37:51Z","timestamp":1727534271000},"page":"103320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Autoreactive B cells remain active despite clinical disease control in rheumatoid arthritis"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-2837","authenticated-orcid":false,"given":"Sam","family":"Neppelenbroek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke J.","family":"Blomberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arieke S.B.","family":"Kampstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost G.K.","family":"van der Hem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W.J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 E.M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5700-5617","authenticated-orcid":false,"given":"Hans U.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103320_bib1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103320_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2024.103320_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41584-020-00543-5","article-title":"Why remission is not enough: underlying disease mechanisms in RA that prevent cure","volume":"17","author":"Schett","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103320_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2024.103320_bib5","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2024.103320_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","article-title":"Comprehensive overview of autoantibody isotype and subclass distribution","volume":"150","author":"Volkov","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103320_bib7","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103320_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.coi.2019.09.005","article-title":"Pathogenic memory plasma cells in autoimmunity","volume":"61","author":"Chang","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jaut.2024.103320_bib9","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ni.3533","article-title":"Defining antigen-specific plasmablast and memory B cell subsets in blood following viral infection and vaccination of humans","volume":"17","author":"Ellebedy","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2024.103320_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2204607119","article-title":"Early human B cell signatures of the primary antibody response to mRNA vaccination","volume":"119","author":"Kardava","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2024.103320_bib11","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.30537","article-title":"Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis","volume":"63","author":"van de Stadt","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103320_bib12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2014-207080","article-title":"Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms","volume":"75","author":"Ajeganova","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103320_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103320_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.42098","article-title":"IgG anti\u2013citrullinated protein antibody variable domain glycosylation increases before the onset of rheumatoid arthritis and stabilizes thereafter: a cross-sectional study encompassing \u223c1,500 samples","volume":"74","author":"Kissel","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103320_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103320_bib16","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103320_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5327","article-title":"Persistently activated, proliferative memory autoreactive b cells promote inflammation in rheumatoid arthritis","volume":"12","author":"Kristyanto","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2024.103320_bib18","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/annrheumdis-2014-207182","article-title":"Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis","volume":"75","author":"Kerkman","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103320_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145516","article-title":"Durable SARS-CoV-2 B cell immunity after mild or severe disease","volume":"131","author":"Ogega","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103320_bib20","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1172\/JCI74351","article-title":"Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals","volume":"124","author":"Kardava","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103320_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhep.2020.01.024","article-title":"Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV","volume":"73","author":"Vanwolleghem","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2024.103320_bib22","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2024.103320_bib23","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41467-021-22210-3","article-title":"SARS-CoV-2 in severe COVID-19 induces a TGF-\u03b2-dominated chronic immune response that does not target itself","volume":"12","author":"Ferreira-Gomes","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2024.103320_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103320_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard.2010.131102","article-title":"Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities","volume":"70","author":"Ioan-Facsinay","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103320_bib26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/annrheumdis-2019-216499","article-title":"Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications","volume":"79","author":"Kissel","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103320_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103320_bib28","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1073\/pnas.91.15.7007","article-title":"Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells","volume":"91","author":"Boussiotis","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2024.103320_bib29","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.271.5253.1289","article-title":"Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers","volume":"271","author":"Matsumoto","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jaut.2024.103320_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab223","article-title":"COVID-19 vaccination and antirheumatic therapy","volume":"60","author":"Arnold","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2024.103320_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","article-title":"Impact of tofacitinib treatment on human B-cells in vitro and in vivo","volume":"77","author":"Rizzi","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2024.103320_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087986","article-title":"JAK inhibitors differentially modulate B cell activation, maturation and function: a comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis","volume":"14","author":"Frede","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103320_bib33","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.3390\/cells11213391","article-title":"Aberrant B cell signaling in autoimmune diseases","volume":"11","author":"Corneth","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jaut.2024.103320_bib34","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/sciadv.abm1759","article-title":"Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation","volume":"8","author":"Kissel","year":"2022","journal-title":"Sci. Adv."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124001549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124001549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:19:05Z","timestamp":1777580345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124001549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"alternative-id":["S0896841124001549"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103320","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoreactive B cells remain active despite clinical disease control in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103320"}}